The JUBILEE trial evaluates a novel treatment regimen combining metformin and sitagliptin (Janumet) followed by insulin glargine (Lantus) in Type 2 Diabetes Mellitus (T2DM) patients. This approach aims to enhance glycaemic control while minimizing hypoglycaemic events compared to traditional therapies involving sulfonylureas. Given the increasing prevalence of T2DM, particularly in Eastern populations, successful outcomes could position this regimen favorably in a competitive market dominated by established therapies. The trial's completion and results may influence prescribing patterns and market dynamics, particularly in regions with high T2DM incidence. Stakeholders should monitor the results for potential shifts in treatment guidelines and market access strategies.